Literature DB >> 10565842

Ethnic differences in N-glucuronidation of nicotine and cotinine.

N L Benowitz1, E J Perez-Stable, I Fong, G Modin, B Herrera, P Jacob.   

Abstract

We previously reported that the metabolism of cotinine, the proximate metabolite of nicotine, is significantly slower in black than in white cigarette smokers. To understand why the metabolism of nicotine and cotinine might differ between blacks and whites, we studied the pattern of nicotine metabolism in blacks and whites. One hundred eight healthy smokers (51 blacks and 57 whites), of similar age, gender distribution, and smoking history, received an i.v. infusion of deuterium-labeled nicotine and cotinine. The clearance of cotinine, the fractional conversion of nicotine to cotinine, and the metabolic clearance of nicotine to cotinine were significantly lower in blacks than in whites. Blacks excreted significantly less nicotine as nicotine-N-glucuronide and less cotinine as cotinine-N-glucuronide than whites, but there was no difference in the excretion of 3'-hydroxycotinine-O-glucuronide. Nicotine and cotinine glucuronidation appeared to be polymorphic, with evidence of slow and fast N-glucuronide formers among blacks but was unimodal with fast conjugators only among whites. Other findings of note included the demonstration of a significant correlation between the distribution volumes of nicotine and cotinine with lean body mass: there was a smaller distribution volume and a shorter half-life for cotinine in women than in men and a smaller volume of distribution of cotinine in blacks than in whites. We conclude that the metabolism of cotinine is slower in blacks than in whites because of both slower oxidative metabolism of nicotine to cotinine (presumably via cytochrome P-450 2A6) and slower N-glucuronidation. Ethnic differences in the metabolism of other drugs undergoing N-glucuronidation should be studied.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565842

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  90 in total

1.  Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Authors:  Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-09-06       Impact factor: 4.335

Review 2.  Hair as a biomarker for exposure to tobacco smoke.

Authors:  W K Al-Delaimy
Journal:  Tob Control       Date:  2002-09       Impact factor: 7.552

3.  How home-smoking habits affect children: a cross-sectional study using urinary cotinine measurement in Italy.

Authors:  Carmela Protano; Roberta Andreoli; Paola Manini; Matteo Vitali
Journal:  Int J Public Health       Date:  2012-03-21       Impact factor: 3.380

4.  Psychological distress and smoking behavior: the nature of the relation differs by race/ethnicity.

Authors:  Marc T Kiviniemi; Heather Orom; Gary A Giovino
Journal:  Nicotine Tob Res       Date:  2010-12-15       Impact factor: 4.244

Review 5.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

6.  Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Authors:  Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia
Journal:  J Natl Cancer Inst       Date:  2012-01-25       Impact factor: 13.506

7.  White blood cell DNA adducts in a cohort of asthmatic children exposed to environmental tobacco smoke.

Authors:  Stephen E Wilson; Glenn Talaska; Robert S Kahn; Brenda Schumann; Jane Khoury; Anthony C Leonard; Bruce P Lanphear
Journal:  Int Arch Occup Environ Health       Date:  2010-03-25       Impact factor: 3.015

8.  Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.

Authors:  Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox
Journal:  Addict Behav       Date:  2012-11-29       Impact factor: 3.913

9.  Utility and relationships of biomarkers of smoking in African-American light smokers.

Authors:  Man Ki Ho; Babalola Faseru; Won S Choi; Nicole L Nollen; Matthew S Mayo; Janet L Thomas; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.